The Experts below are selected from a list of 52602 Experts worldwide ranked by ideXlab platform
Bob Olsson - One of the best experts on this subject based on the ideXlab platform.
-
CSF levels of YKL-40 are increased in MS and decrease with Immunosuppressive Treatment
Journal of Neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
-
CSF levels of YKL-40 are increased in MS and replaces with Immunosuppressive Treatment.
Journal of neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
Camillo Ribi - One of the best experts on this subject based on the ideXlab platform.
-
Pneumococcal polysaccharide vaccination in adults undergoing Immunosuppressive Treatment for inflammatory diseases – a longitudinal study
Arthritis research & therapy, 2015Co-Authors: Lara Fischer, Patricia Francis Gerstel, Antoine Poncet, Claire-anne Siegrist, Emmanuel Laffitte, Cem Gabay, Joerg Dieter Seebach, Camillo RibiAbstract:Introduction Patients undergoing Immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of Immunosuppressive Treatment. Often, however, the Treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during Immunosuppressive Treatment. The objectives of this study were to determine the percentage of vaccine-naive, immunosuppressed adults with inflammatory diseases seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.
-
pneumococcal polysaccharide vaccination in adults undergoing Immunosuppressive Treatment for inflammatory diseases a longitudinal study
Arthritis Research & Therapy, 2015Co-Authors: Lara Fischer, Patricia Francis Gerstel, Antoine Poncet, Claire-anne Siegrist, Emmanuel Laffitte, Cem Gabay, Joerg Dieter Seebach, Camillo RibiAbstract:Introduction Patients undergoing Immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of Immunosuppressive Treatment. Often, however, the Treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during Immunosuppressive Treatment. The objectives of this study were to determine the percentage of vaccine-naive, immunosuppressed adults with inflammatory diseases seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.
Clas Malmeström - One of the best experts on this subject based on the ideXlab platform.
-
CSF levels of YKL-40 are increased in MS and decrease with Immunosuppressive Treatment
Journal of Neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
-
CSF levels of YKL-40 are increased in MS and replaces with Immunosuppressive Treatment.
Journal of neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
Lara Fischer - One of the best experts on this subject based on the ideXlab platform.
-
Pneumococcal polysaccharide vaccination in adults undergoing Immunosuppressive Treatment for inflammatory diseases – a longitudinal study
Arthritis research & therapy, 2015Co-Authors: Lara Fischer, Patricia Francis Gerstel, Antoine Poncet, Claire-anne Siegrist, Emmanuel Laffitte, Cem Gabay, Joerg Dieter Seebach, Camillo RibiAbstract:Introduction Patients undergoing Immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of Immunosuppressive Treatment. Often, however, the Treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during Immunosuppressive Treatment. The objectives of this study were to determine the percentage of vaccine-naive, immunosuppressed adults with inflammatory diseases seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.
-
pneumococcal polysaccharide vaccination in adults undergoing Immunosuppressive Treatment for inflammatory diseases a longitudinal study
Arthritis Research & Therapy, 2015Co-Authors: Lara Fischer, Patricia Francis Gerstel, Antoine Poncet, Claire-anne Siegrist, Emmanuel Laffitte, Cem Gabay, Joerg Dieter Seebach, Camillo RibiAbstract:Introduction Patients undergoing Immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of Immunosuppressive Treatment. Often, however, the Treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during Immunosuppressive Treatment. The objectives of this study were to determine the percentage of vaccine-naive, immunosuppressed adults with inflammatory diseases seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.
Markus Axelsson - One of the best experts on this subject based on the ideXlab platform.
-
CSF levels of YKL-40 are increased in MS and decrease with Immunosuppressive Treatment
Journal of Neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
-
CSF levels of YKL-40 are increased in MS and replaces with Immunosuppressive Treatment.
Journal of neuroimmunology, 2014Co-Authors: Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob OlssonAbstract:The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to Immunosuppressive Treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab Treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by Immunosuppressive Treatment.
